Left ventricular assist device (LVAD) has become an established therapy for end-stage heart failure, bridging patients to cardiac transplantation or to destiny in transplant-ineligible patients. New generation pumps continue to improve outcomes with 84% 1-year survival reported for the HeartWare Ventricular Assist Device (HVAD, HeartWare Inc, Framingham, MA).
This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.
